Kidney Cancer
Conditions
Brief summary
An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.
Interventions
PROCEDURESurgical intervention
Surgical intervention with collection of tissue material
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient * Localized kidney tumors\> T1a * Patient having signed an informed consent * Patient affiliated to a health insurance plan * Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes
Exclusion criteria
* Metastatic carcinoma from the outset * Contraindication to performing a TAP CT with injection of contrast product * Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.) * Subject under legal protection * Subject under tutorship or curatorship * Pregnancy * Feeding with milk
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression of MFI2-AS1 | 36 month | To assess the link between tumor expression of MFI2-AS1 in patients with localized clear cell kidney carcinoma and the occurrence of relapse |
Countries
France
Contacts
Primary ContactTRICARD Thibault
Backup ContactMALOUF Gabriel
Outcome results
None listed